cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.5950171
title: Left Main Coronary Artery Embolism after Transcatheter Aortic Valve Replacement: Insights from Multimodal Intracoronary Imagings

description: Left Main Coronary Artery Embolism after Transcatheter Aortic Valve Replacement: Insights from Multimodal Intracoronary Imagings
DOI: 10.6084/m9.figshare.5950171.v1
title: Left Main Coronary Artery Embolism after Transcatheter Aortic Valve Replacement: Insights from Multimodal Intracoronary Imagings

description: Left Main Coronary Artery Embolism after Transcatheter Aortic Valve Replacement: Insights from Multimodal Intracoronary Imagings
DOI: 10.6084/m9.figshare.5950141
title: Combined Transcatheter Closure of Aorto-Iliac Graft Pseudoaneurysm and Aortic Valve Implantation

description: Combined Transcatheter Closure of Aorto-Iliac Graft Pseudoaneurysm and Aortic Valve Implantation
DOI: 10.6084/m9.figshare.5950141.v2
title: Combined Transcatheter Closure of Aorto-Iliac Graft Pseudoaneurysm and Aortic Valve Implantation

description: Combined Transcatheter Closure of Aorto-Iliac Graft Pseudoaneurysm and Aortic Valve Implantation
DOI: 10.6084/m9.figshare.6267287
title: The Clinical Dilemma of Cardiac Fibroelastic Papilloma

description: Cardiac papillary fibroelastomas (CPFEs) are one of the most challenging cardiovascular abnormalities that can be encountered. Although uncommon, some studies have reported them to be more prevalent than myxomas. Despite being frequently asymptomatic, they are capable of resulting in systemic emboli, particularly cerebrovascular accidents. They are often found incidentally in asymptomatic individuals or in patients in whom other risk factors for systemic emboli are present. At present there are virtually no prospective or controlled data available regarding their risk for subsequent events, benefit from surgical intervention or response to antiplatelet or anticoagulant medications. Absent firm guidance for management, clinical judgment on a case-by-case basis is paramount. CPFE are lesions that can present that most difficult decision of whether or not to perform cardiac surgery in a perfectly asymptomatic individual. In this article, we will discuss the morphology and pathology, clinical manifestations, diagnosis, treatment, and prognosis of cardiac papillary fibroelastoma.
DOI: 10.6084/m9.figshare.5950141.v1
title: Combined transcatheter closure of aorto-iliac graft pseudoaneurysm and aortic valve implantation

description: Combined transcatheter closure of aorto-iliac graft pseudoaneurysm and aortic valve implantation
DOI: 10.6084/m9.figshare.6267287.v2
title: The Clinical Dilemma of Cardiac Fibroelastic Papilloma

description: Cardiac papillary fibroelastomas (CPFEs) are one of the most challenging cardiovascular abnormalities that can be encountered. Although uncommon, some studies have reported them to be more prevalent than myxomas. Despite being frequently asymptomatic, they are capable of resulting in systemic emboli, particularly cerebrovascular accidents. They are often found incidentally in asymptomatic individuals or in patients in whom other risk factors for systemic emboli are present. At present there are virtually no prospective or controlled data available regarding their risk for subsequent events, benefit from surgical intervention or response to antiplatelet or anticoagulant medications. Absent firm guidance for management, clinical judgment on a case-by-case basis is paramount. CPFE are lesions that can present that most difficult decision of whether or not to perform cardiac surgery in a perfectly asymptomatic individual. In this article, we will discuss the morphology and pathology, clinical manifestations, diagnosis, treatment, and prognosis of cardiac papillary fibroelastoma.
DOI: 10.6084/m9.figshare.6267287.v1
title: The Clinical Dilemma of Cardiac Fibroelastic Papilloma

description: Cardiac papillary fibroelastomas (CPFEs) are one of the most challenging cardiovascular abnormalities that can be encountered. Although uncommon, some studies have reported them to be more prevalent than myxomas. Despite being frequently asymptomatic, they are capable of resulting in systemic emboli, particularly cerebrovascular accidents. They are often found incidentally in asymptomatic individuals or in patients in whom other risk factors for systemic emboli are present. At present there are virtually no prospective or controlled data available regarding their risk for subsequent events, benefit from surgical intervention or response to antiplatelet or anticoagulant medications. Absent firm guidance for management, clinical judgment on a case-by-case basis is paramount. CPFE are lesions that can present that most difficult decision of whether or not to perform cardiac surgery in a perfectly asymptomatic individual. In this article, we will discuss the morphology and pathology, clinical manifestations, diagnosis, treatment, and prognosis of cardiac papillary fibroelastoma.
DOI: 10.6084/m9.figshare.12685646.v1
title: Brachychirotherium trackways from Ruditayoj, Bolivia

description: These trackway models are supplement to the study of Ruditayoj Brachychirotherium trackways, probably made by 'rauisuchians' (previously identified as thyreophoran tracks). The study was carried out by Apesteguía, Riguetti, Citton, Veiga, Poiré, Zacarías, Sempere and de Valais, 2020. The Ruditayoj-Tunasniyoj-Estancia Uyuni fossil area: A Triassic giant chirotheriid tracksite and reinterpretation of thyreophoran tracks from Bolivia. Historical Biology.
DOI: 10.6084/m9.figshare.12685646
title: Brachychirotherium trackways from Ruditayoj, Bolivia

description: These trackway models are supplement to the study of Ruditayoj Brachychirotherium trackways, probably made by 'rauisuchians' (previously identified as thyreophoran tracks). The study was carried out by Apesteguía, Riguetti, Citton, Veiga, Poiré, Zacarías, Sempere and de Valais, 2020. The Ruditayoj-Tunasniyoj-Estancia Uyuni fossil area: A Triassic giant chirotheriid tracksite and reinterpretation of thyreophoran tracks from Bolivia. Historical Biology.
DOI: 10.6084/m9.figshare.7026098
title: Impact of Transcatheter Mitral Valve Repair on Left Ventricular Remodeling in Secondary Mitral Regurgitation: A Meta-Analysis

description: <b>Background:</b> Secondary mitral regurgitation (MR) arises from left ventricular (LV) dilatation and remodeling, and commonly is treated with transcatheter mitral valve repair. We examined the impact of MitraClip on reverse cardiac remodeling in patients with severe, symptomatic secondary MR. <b>Methods:</b>: An electronic search was performed through January 2018 for studies that reported cardiac chamber dimensions prior to and after treatment with MitraClip in patients with secondary MR. The mean difference (MD) with 95% CI was calculated using fixed or random inverse variance models. Outcomes of interest were changes in LV end-systolic and end-diastolic volumes (LVESV, LVEDV) and dimensions (LVESD, LVEDD). Secondary outcomes included left atrial (LA) volume, systolic pulmonary artery pressure (sPAP) and LV ejection fraction (LVEF). <b>Results:</b> A total of 16 studies with 1,266 patients were included in the present analysis. The weighted mean follow-up period (±SD) was 11.5 ± 7.2 months. MitraClip was associated with significant reduction in LVEDV (−14.24 ml, 95% CI [−22.53, −5.94], <i>p</i> = 0.0008), LVESV (−7.67 ml, CI [−12.30, −3.03], <i>p</i> = 0.001), LVEDD (−2.92 mm [−3.65, −2.19 mm], <i>p</i> p = 0.0002). MitraClip was also associated with reduction in LA volume (−16.36 ml [23.23, −9.49 ml], <i>p</i> p p = 0.004). <b>Conclusions:</b> In patients with severe symptomatic secondary MR, MitraClip is associated with modest, but favorable LV and LA reverse remodeling. The impact of these changes on clinical outcomes deserves further study.
DOI: 10.6084/m9.figshare.7026098.v3
title: Impact of Transcatheter Mitral Valve Repair on Left Ventricular Remodeling in Secondary Mitral Regurgitation: A Meta-Analysis

description: <b>Background:</b> Secondary mitral regurgitation (MR) arises from left ventricular (LV) dilatation and remodeling, and commonly is treated with transcatheter mitral valve repair. We examined the impact of MitraClip on reverse cardiac remodeling in patients with severe, symptomatic secondary MR. <b>Methods:</b>: An electronic search was performed through January 2018 for studies that reported cardiac chamber dimensions prior to and after treatment with MitraClip in patients with secondary MR. The mean difference (MD) with 95% CI was calculated using fixed or random inverse variance models. Outcomes of interest were changes in LV end-systolic and end-diastolic volumes (LVESV, LVEDV) and dimensions (LVESD, LVEDD). Secondary outcomes included left atrial (LA) volume, systolic pulmonary artery pressure (sPAP) and LV ejection fraction (LVEF). <b>Results:</b> A total of 16 studies with 1,266 patients were included in the present analysis. The weighted mean follow-up period (±SD) was 11.5 ± 7.2 months. MitraClip was associated with significant reduction in LVEDV (−14.24 ml, 95% CI [−22.53, −5.94], <i>p</i> = 0.0008), LVESV (−7.67 ml, CI [−12.30, −3.03], <i>p</i> = 0.001), LVEDD (−2.92 mm [−3.65, −2.19 mm], <i>p</i> p = 0.0002). MitraClip was also associated with reduction in LA volume (−16.36 ml [23.23, −9.49 ml], <i>p</i> p p = 0.004). <b>Conclusions:</b> In patients with severe symptomatic secondary MR, MitraClip is associated with modest, but favorable LV and LA reverse remodeling. The impact of these changes on clinical outcomes deserves further study.
DOI: 10.6084/m9.figshare.7073267.v3
title: Impact of Atrial Fibrillation on the Outcomes after MitraClip®: A Meta-Analysis

description: <b>Background:</b> Atrial fibrillation (AF) has been associated with worse outcomes in patients undergoing mitral valve surgery for mitral regurgitation. The impact of preexisting AF on the outcomes after transcatheter mitral valve repair with MitraClip® (Abbott Vascular, Santa Clara, CA, USA) has not been well studied. <b>Methods:</b> An electronic search was performed until December 2017 for studies reporting outcomes after MitraClip® in patients with AF versus those with no AF. Outcomes of interest included all-cause mortality, stroke and major adverse cardiovascular events (MACE) defined as the composite outcome of death, stroke, and myocardial infarction at the longest follow-up reported. <b>Results:</b> A total of four studies including 1473 patients (AF n = 697; no AF n = 776) were included. There was no difference in procedural success or procedural time between patients with AF versus those without AF. AF was associated with increased mortality after MitraClip® compared with patients with no AF (OR 1.54, 95% CI (1.16, 2.04), <i>p</i> = 0.003, <i>I</i> <sup>2</sup> = 0%) over a mean follow-up period of 10.2 months. In a sensitivity analysis excluding early postoperative (30-day) outcomes, AF remained associated with higher mortality (OR 1.53, 95% CI (1.15, 2.03), <i>p</i> = 0.003, <i>I</i> <sup>2</sup> = 19%). AF was associated with a higher incidence of MACE after MitraClip® (OR 1.46, 95% CI (1.03, 2.07), <i>p</i> = 0.03, <i>I</i> <sup>2</sup> = 13%). No difference was observed in the risk of stroke between patients with versus without AF after MitraClip® (OR 1.13, 95%CI (0.36, 3.56), <i>p</i> = 0.84, <i>I</i> <sup>2</sup> = 37%). <b>Conclusions:</b> Compared with patients without AF, patients with preexisting AF are at higher risk of death and MACE after MitraClip®.
DOI: 10.6084/m9.figshare.6686864.v1
title: Plug-Coil-Plug Technique for Percutaneous Closure of a Complex Aortic Pseudoaneurysm

description: Plug-Coil-Plug Technique for Percutaneous Closure of a Complex Aortic Pseudoaneurysm
DOI: 10.6084/m9.figshare.7026098.v2
title: Impact of Transcatheter Mitral Valve Repair on Left Ventricular Remodeling in Secondary Mitral Regurgitation: A Meta-Analysis

description: <b>Background</b>: Secondary mitral regurgitation (MR) arises from left ventricular (LV) dilatation and remodeling, and commonly is treated with transcatheter mitral valve repair. We examined the impact of MitraClip on reverse cardiac remodeling in patients with severe, symptomatic secondary MR. <b>Methods</b>: An electronic search was performed through January 2018 for studies that reported cardiac chamber dimensions prior to and after treatment with MitraClip in patients with secondary MR. The mean difference (MD) with 95% CI was calculated using fixed or random inverse variance models. Outcomes of interest were changes in LV end-systolic and end-diastolic volumes (LVESV, LVEDV) and dimensions (LVESD, LVEDD). Secondary outcomes included left atrial (LA) volume, systolic pulmonary artery pressure (sPAP) and LV ejection fraction (LVEF). <b>Results</b>: A total of 16 studies with 1,266 patients were included in the present analysis. The weighted mean follow-up period (±SD) was 11.5 ± 7.2 months. MitraClip was associated with significant reduction in LVEDV (−14.24 ml, 95% CI [−22.53, −5.94], <i>p</i> = 0.0008), LVESV (−7.67 ml, CI [−12.30, −3.03], <i>p</i> = 0.001), LVEDD (−2.92 mm [−3.65, −2.19 mm], <i>p</i> p = 0.0002). MitraClip was also associated with reduction in LA volume (−16.36 ml [23.23, −9.49 ml], <i>p</i> p p = 0.004). <b>Conclusions</b>: In patients with severe symptomatic secondary MR, MitraClip is associated with modest, but favorable LV and LA reverse remodeling. The impact of these changes on clinical outcomes deserves further study.
DOI: 10.6084/m9.figshare.6686864
title: Plug-Coil-Plug Technique for Percutaneous Closure of a Complex Aortic Pseudoaneurysm

description: Plug-Coil-Plug Technique for Percutaneous Closure of a Complex Aortic Pseudoaneurysm
DOI: 10.6084/m9.figshare.7073267
title: Impact of Atrial Fibrillation on the Outcomes after MitraClip®: A Meta-Analysis

description: <b>Background:</b> Atrial fibrillation (AF) has been associated with worse outcomes in patients undergoing mitral valve surgery for mitral regurgitation. The impact of preexisting AF on the outcomes after transcatheter mitral valve repair with MitraClip® (Abbott Vascular, Santa Clara, CA, USA) has not been well studied. <b>Methods:</b> An electronic search was performed until December 2017 for studies reporting outcomes after MitraClip® in patients with AF versus those with no AF. Outcomes of interest included all-cause mortality, stroke and major adverse cardiovascular events (MACE) defined as the composite outcome of death, stroke, and myocardial infarction at the longest follow-up reported. <b>Results:</b> A total of four studies including 1473 patients (AF n = 697; no AF n = 776) were included. There was no difference in procedural success or procedural time between patients with AF versus those without AF. AF was associated with increased mortality after MitraClip® compared with patients with no AF (OR 1.54, 95% CI (1.16, 2.04), <i>p</i> = 0.003, <i>I</i> <sup>2</sup> = 0%) over a mean follow-up period of 10.2 months. In a sensitivity analysis excluding early postoperative (30-day) outcomes, AF remained associated with higher mortality (OR 1.53, 95% CI (1.15, 2.03), <i>p</i> = 0.003, <i>I</i> <sup>2</sup> = 19%). AF was associated with a higher incidence of MACE after MitraClip® (OR 1.46, 95% CI (1.03, 2.07), <i>p</i> = 0.03, <i>I</i> <sup>2</sup> = 13%). No difference was observed in the risk of stroke between patients with versus without AF after MitraClip® (OR 1.13, 95%CI (0.36, 3.56), <i>p</i> = 0.84, <i>I</i> <sup>2</sup> = 37%). <b>Conclusions:</b> Compared with patients without AF, patients with preexisting AF are at higher risk of death and MACE after MitraClip®.
DOI: 10.6084/m9.figshare.7073267.v2
title: Impact of Atrial Fibrillation on the Outcomes after MitraClip®: A Meta-Analysis

description: <b>Background</b>: Atrial fibrillation (AF) has been associated with worse outcomes in patients undergoing mitral valve surgery for mitral regurgitation. The impact of preexisting AF on the outcomes after transcatheter mitral valve repair with MitraClip® (Abbott Vascular, Santa Clara, CA, USA) has not been well studied. <b>Methods</b>: An electronic search was performed until December 2017 for studies reporting outcomes after MitraClip® in patients with AF versus those with no AF. Outcomes of interest included all-cause mortality, stroke and major adverse cardiovascular events (MACE) defined as the composite outcome of death, stroke, and myocardial infarction at the longest follow-up reported. <b>Results</b>: A total of four studies including 1473 patients (AF n = 697; no AF n = 776) were included. There was no difference in procedural success or procedural time between patients with AF versus those without AF. AF was associated with increased mortality after MitraClip® compared with patients with no AF (OR 1.54, 95% CI (1.16, 2.04), <i>p</i> = 0.003, <i>I</i><sup>2</sup> = 0%) over a mean follow-up period of 10.2 months. In a sensitivity analysis excluding early postoperative (30-day) outcomes, AF remained associated with higher mortality (OR 1.53, 95% CI (1.15, 2.03), <i>p</i> = 0.003, <i>I</i><sup>2</sup> = 19%). AF was associated with a higher incidence of MACE after MitraClip® (OR 1.46, 95% CI (1.03, 2.07), <i>p</i> = 0.03, <i>I</i><sup>2</sup> = 13%). No difference was observed in the risk of stroke between patients with versus without AF after MitraClip® (OR 1.13, 95%CI (0.36, 3.56), <i>p</i> = 0.84, <i>I</i><sup>2</sup> = 37%). <b>Conclusions</b>: Compared with patients without AF, patients with preexisting AF are at higher risk of death and MACE after MitraClip®.
DOI: 10.6084/m9.figshare.6955103
title: Emergent Transcatheter Aortic Valve Replacement for the Treatment of Severe Aortic Stenosis Patients Presenting With Cardiogenic Shock or Cardiac Arrest; A Case Series

description: <b>Background:</b> Patients with severe aortic stenosis (AS) often present acutely with decompensated heart failure, cardiogenic shock or cardiac arrest requiring immediate intervention. Transcatheter aortic valve replacement (TAVR) has been effectively utilized to treat such patients. However, data on emergent TAVR remain scarce. <b>Methods:</b> We report a cases series of consecutive patients who underwent emergent TAVR between July 2016 and December 2017 at our institution. We describe the patients’ characteristics, the rational for intervention, procedural details, and mid-term outcomes. <b>Results:</b> Nine patients underwent emergent TAVR during the study’s period. Mean age was 80.6 ± 9.9, 44% were males, mean left ventricular ejection fraction was 42.8 ± 19.1. The rational for emergent intervention was cardiogenic shock in 6 (67%), cardiac arrest in 2 (22%), and both in 1 (11%). Mean transaortic valve gradient was 49.8 ± 20.4 mmHg. The mean time from event to TAVR time was 9.9 hours (range 2–14). Balloon aortic valvuloplasty was utilized pre-TAVR in four patients (44%), and peri-procedural percutaneous assist devices were used in three patients (33%). Sapien S3 was the most used valve (89%). Procedural success was achieved in 100%, and 8/9 patients (89%) survived to discharge. All surviving patients were alive and in class I/II New York Heart Association (NYHA) symptom category both at 1 month and a mean follow-up of 8.4 ± 3.7 months. <b>Conclusions:</b> TAVR may provide a feasible and effective treatment for patients with decompensated AS requiring emergent intervention. Further studies are needed to identify the optimal algorithm for the management of these patients.
DOI: 10.6084/m9.figshare.6955103.v1
title: Emergent Transcatheter Aortic Valve Replacement for the Treatment of Severe Aortic Stenosis Patients Presenting With Cardiogenic Shock or Cardiac Arrest; A Case Series

description: <b>Background:</b> Patients with severe aortic stenosis (AS) often present acutely with decompensated heart failure, cardiogenic shock or cardiac arrest requiring immediate intervention. Transcatheter aortic valve replacement (TAVR) has been effectively utilized to treat such patients. However, data on emergent TAVR remain scarce. <b>Methods:</b> We report a cases series of consecutive patients who underwent emergent TAVR between July 2016 and December 2017 at our institution. We describe the patients’ characteristics, the rational for intervention, procedural details, and mid-term outcomes. <b>Results:</b> Nine patients underwent emergent TAVR during the study’s period. Mean age was 80.6 ± 9.9, 44% were males, mean left ventricular ejection fraction was 42.8 ± 19.1. The rational for emergent intervention was cardiogenic shock in 6 (67%), cardiac arrest in 2 (22%), and both in 1 (11%). Mean transaortic valve gradient was 49.8 ± 20.4 mmHg. The mean time from event to TAVR time was 9.9 hours (range 2–14). Balloon aortic valvuloplasty was utilized pre-TAVR in four patients (44%), and peri-procedural percutaneous assist devices were used in three patients (33%). Sapien S3 was the most used valve (89%). Procedural success was achieved in 100%, and 8/9 patients (89%) survived to discharge. All surviving patients were alive and in class I/II New York Heart Association (NYHA) symptom category both at 1 month and a mean follow-up of 8.4 ± 3.7 months. <b>Conclusions:</b> TAVR may provide a feasible and effective treatment for patients with decompensated AS requiring emergent intervention. Further studies are needed to identify the optimal algorithm for the management of these patients.
DOI: 10.6084/m9.figshare.6399920
title: Transcatheter Aortic Valve Thrombosis Causing Trans-Valvar Regurgitation

description: Transcatheter Aortic Valve Thrombosis Causing Trans-Valvar Regurgitation
DOI: 10.6084/m9.figshare.6399920.v2
title: Transcatheter Aortic Valve Thrombosis Causing Trans-Valvar Regurgitation

description: Transcatheter Aortic Valve Thrombosis Causing Trans-Valvar Regurgitation
DOI: 10.6084/m9.figshare.6399920.v1
title: Transcatheter aortic valve thrombosis causing trans-valvar regurgitation

description: Transcatheter aortic valve thrombosis causing trans-valvar regurgitation
DOI: 10.6084/m9.figshare.13135061.v1
title: R0310_20191125a_videos

description: Rat 0310, skilled reaching data collected in Leventhal laboratory by Alexandra Bova
DOI: 10.6084/m9.figshare.13138583
title: Oak Decline Naji.xlsx

description: This file is consist of all data that support the findings of this study.
DOI: 10.6084/m9.figshare.13138367
title: data.zip

description: EEG data for BCI experiments
DOI: 10.6084/m9.figshare.12644000.v1
title: Conservation_ConSurf.xlsx

description: Data from the paper "Mutational Survivorship Bias: The case of PNKP"-PNKP Conservation Scores (ConSurf 2016)-PNKP gnomAD and Metadome server-Homology & HotSpot Analysis<br>
DOI: 10.21227/cj43-mc45
title: Charge Limiting Research Data

description: Capacity measurement data for research project The Effectiveness of Charge Limiting and Partial Charge Limiting in Smartphones
DOI: 10.21227/jmc1-nk05
title: Charge Limiting Research Data

description: Capacity measurement data for research project The Effectiveness of Charge Limiting and Partial Charge Limiting in Smartphones
DOI: 10.21227/vdhg-xk70
title: Charge Limiting Research Data

description: Capacity measurement data for research project The Effectiveness of Charge Limiting and Partial Charge Limiting in Smartphones
DOI: 10.6084/m9.figshare.13137122
title: R0311_20191117a_videos

description: Rat 0311, skilled reaching data collected in Leventhal laboratory by Alexandra Bova
DOI: 10.6084/m9.figshare.13137122.v1
title: R0311_20191117a_videos

description: Rat 0311, skilled reaching data collected in Leventhal laboratory by Alexandra Bova
DOI: 10.21227/d48c-0920
title: Charge Limiting Research Data

description: Capacity measurement data for research project The Effectiveness of Charge Limiting and Partial Charge Limiting in Smartphones
DOI: 10.6084/m9.figshare.3761562.v1653
title: Online Labour Index: Measuring the Online Gig Economy for Policy and Research

description: Data repository for the data underlying the Online Labour Index. See http://ilabour.oii.ox.ac.uk online-labour-index/ for details.